Thyroid hormone receptor-beta agonists: new MASLD therapies on the horizon

Introduction Metabolic dysfunction-associated steatotic liver disease (MASLD) has emerged as the leading chronic liver disease worldwide in the past decade.1 The spectrum of liver diseases in MASLD ranges from metabolic dysfunction-associated simple steatosis to steatohepatitis (MASH), advanced fibrosis, cirrhosis and hepatocellular carcinoma. The pathophysiology of MASLD involves many diverse pathways, including lipotoxicity, insulin resistance, gut dysbiosis, dietary factors, and innate and adaptive immunity, all reflecting the critical aspects of the disease process.2 3 Liver inflammation and progressive fibrosis, as observed in many patients with MASH, are considered crucial driving forces of disease progression, and therefore patients with MASH are the key target population for the development of new therapeutic drugs.2 4 Identification of patients with MASH has historically been dependent on liver biopsy and analysis of liver histology, although promising biomarker panels have recently been developed5...
Source: Gut - Category: Gastroenterology Authors: Tags: Gut Leading article Source Type: research